Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease

NCT04785300 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04785300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04785300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 6, 2022
Completion date
December 31, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild cognitive impairment